Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Humans: What we say and think does not always predict what we do

Posted on March 22nd, 2017 by

Pharma R&D

doctor-563428_640

 

Actions speak louder than words. This is a useful adage and was a family mantra. It has been useful to keep this in mind in so many situations, in both my personal and professional life. Continue reading “Humans: What we say and think does not always predict what we do” »

Building a balanced search formula for pharmacovigilance and literature monitoring

Posted on March 21st, 2017 by

Pharmacovigilance

Bbinary PV webinar

Adverse drug reactions are an important risk for patient safety and have significant impact on the costs of health systems. A rise in number of diseases has consequently led to a rise in number of drug consumption, which has also brought about an increase in the number of adverse drug events and drug toxicity cases. Continue reading “Building a balanced search formula for pharmacovigilance and literature monitoring” »

Targeting Rare Diseases

Posted on March 20th, 2017 by

Pharma R&D

darts-102919_640

What is known as a “rare” disease might affect anywhere between a couple hundred to a couple hundred thousand people here in the U.S. And it’s estimated that as much as 10% of the nation’s population has one of the thousands of known rare diseases, most of which are genetic. Continue reading “Targeting Rare Diseases” »

Building PV SOPs: Where to start?

Posted on March 17th, 2017 by

Pharmacovigilance

PV blog post

Having a set of operating standards defined through Quality Documents (QDs) is the only route to compliance and performance. QDs are defined as documents such as Policies, SOPs, Work Instructions (WINs), Manuals, Charters and Memo to File. Continue reading “Building PV SOPs: Where to start?” »

Lessons Learned from a Clinical Trial Failure

Posted on March 14th, 2017 by

Chemistry

medical-1572978_640

Revisiting failed clinical trials is important because these studies may generate new insights into drug research and development, leading to effective new treatments. Researchers in the recent IMPROVE-IT trial learned valuable lessons from the failure of the earlier ENHANCE study Continue reading “Lessons Learned from a Clinical Trial Failure” »

Making Medicine More Precise

Posted on March 13th, 2017 by

Pharma R&D

puzzle-654957_640

Precision medicine, which takes the individual into account like never before, has been a thrilling development in the field of medicinal research. It is an area that has shown particular promise in the treatment of cancer, Continue reading “Making Medicine More Precise” »

  1. 1
  2. 2
  3. 3
  4. 34


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.